Top

Journal of Endocrinological Investigation

Published in:

01-12-2018 | Review

Adverse effects of media reports on the treatment of osteoporosis

Authors: Cristiana Cipriani, Jessica Pepe, Salvatore Minisola, E. Michael Lewiecki

Published in: Journal of Endocrinological Investigation | Issue 12/2018

Abstract

Purpose

The review focused on the role that media reporting plays in the level of public awareness about osteoporosis and its influence on osteoporosis treatment decisions.

Methods

We reviewed the literature on the role of media on three main aspects influencing patient adherence to osteoporosis treatment: the awareness of osteoporosis as a major health problem, the perception of the effectiveness of osteoporosis medications, and the fear of adverse effects with osteoporosis medications.

Results

A review of the literature confirmed what is routinely observed in clinical practice—that media report can strongly influence the level of awareness of osteoporosis and fracture risk. Inadequate and/or incorrect information on osteoporosis in the media are associated with a low level of awareness of the disease. High-risk patients may have a poor understanding of the need for treatment. Alarming information in the media over the last 2 decades regarding effectiveness and safety of long-term osteoporosis treatment is associated with reduction in the use of osteoporosis medications.

Conclusions

There is a gap between the application of clinical recommendations and patient perceptions of osteoporosis and its treatment. There is a need for better education of patients and practitioners aimed at recognizing the serious consequences of fractures and understanding the expected benefits and potential risks of treatment. Media reports that disseminate evidence-based information on the balance of benefits and risks could help to reduce the osteoporosis treatment gap and mitigate the crisis in osteoporosis care.

Khosla S, Hofbauer LC (2017) Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(17)30188-2 CrossRefPubMedPubMedCentral

Adler RA (2016) Osteoporosis treatment: complexities and challenges. J Endocrinol Invest 39(7):719–720. https://doi.org/10.1007/s40618-016-0437-5 CrossRefPubMed

Vescini F, Attanasio R, Balestrieri A, Bandeira F, Bonadonna S, Camozzi V, Cassibba S, Cesareo R, Chiodini I, Francucci CM, Gianotti L, Grimaldi F, Guglielmi R, Madeo B, Marcocci C, Palermo A, Scillitani A, Vignali E, Rochira V, Zini M (2016) Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. J Endocrinol Investig 39(7):807–834. https://doi.org/10.1007/s40618-016-0434-8 CrossRef

Cairoli E, Palmieri S, Goggi G, Roggero L, Arosio M, Chiodini I, Eller-Vainicher C (2018) Denosumab or oral bisphosphonates in primary osteoporosis: a “real-life” study. J Endocrinol Investig. https://doi.org/10.1007/s40618-018-0829-9 CrossRef

Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Brookhart MA (2005) Compliance with osteoporosis medications. Arch Intern Med 165(20):2414–2419. https://doi.org/10.1001/archinte.165.20.2414 CrossRefPubMed

Wysowski DK, Greene P (2013) Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002–2012. Bone 57(2):423–428. https://doi.org/10.1016/j.bone.2013.09.008 CrossRefPubMed

Lewiecki EM, Binkley N (2016) What we don’t know about osteoporosis. J Endocrinol Investig 39(5):491–493. https://doi.org/10.1007/s40618-016-0442-8 CrossRef

Jha S, Wang Z, Laucis N, Bhattacharyya T (2015) Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996–2012: an ecological analysis. J Bone Miner Res 30(12):2179–2187. https://doi.org/10.1002/jbmr.2565 CrossRefPubMed

Cipriani C, Pepe J, Bertoldo F, Bianchi G, Cantatore FP, Corrado A, Di Stefano M, Frediani B, Gatti D, Giustina A, Porcelli T, Isaia G, Rossini M, Nieddu L, Minisola S, Girasole G, Pedrazzoni M (2017) The epidemiology of osteoporosis in Italian postmenopausal women according to the National Bone Health Alliance (NBHA) diagnostic criteria: a multicenter cohort study. J Endocrinol Investig. https://doi.org/10.1007/s40618-017-0761-4 CrossRef

10.

Feldstein AC, Schneider J, Smith DH, Vollmer WM, Rix M, Glauber H, Boardman DL, Herson M (2008) Harnessing stakeholder perspectives to improve the care of osteoporosis after a fracture. Osteoporos 19(11):1527–1540. https://doi.org/10.1007/s00198-008-0605-3 CrossRef

11.

Barker KL, Toye F, Lowe CJ (2016) A qualitative systematic review of patients’ experience of osteoporosis using meta-ethnography. Arch Osteoporos 11(1):33. https://doi.org/10.1007/s11657-016-0286-z CrossRefPubMedPubMedCentral

12.

Moyer CA, Vishnu LO, Sonnad SS (2001) Providing health information to women. The role of magazines. Int J Technol Assess Health Care 17(1):137–145CrossRef

13.

Wallace LS, Ballard JE (2003) Osteoporosis coverage in selected women’s magazines and newspapers, 1998–2001. Am J Health Behav 27(1):75–83CrossRef

14.

Edwards BJ, Iris M, Ferkel E, Feinglass J (2006) Postmenopausal women with minimal trauma fractures are unapprised of the existence of low bone mass or osteoporosis. Maturitas 53(3):260–266. https://doi.org/10.1016/j.maturitas.2005.05.008 CrossRefPubMed

15.

Gaines JM, Marx KA, Caudill J, Parrish S, Landsman J, Narrett M, Parrish JM (2010) Older men’s knowledge of osteoporosis and the prevalence of risk factors. J Clin Densitom 13(2):204–209. https://doi.org/10.1016/j.jocd.2010.01.004 CrossRefPubMed

16.

Nadler M, Alibhai S, Catton P, Catton C, To MJ, Jones JM (2013) Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer. BJU Int 111(8):1301–1309. https://doi.org/10.1111/j.1464-410X.2012.11777.x CrossRefPubMed

17.

Adler RA, Hochberg MC (2011) Glucocorticoid-induced osteoporosis in men. J Endocrinol Invest 34(6):481–484. https://doi.org/10.3275/7753 CrossRefPubMed

18.

Harvey NC, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster JY, Rizzoli R, Cooper C, Kanis JA (2017) Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int 28(5):1507–1529. https://doi.org/10.1007/s00198-016-3894-y CrossRefPubMedPubMedCentral

19.

Alliance NBH (2016) National Bone Health Alliance: Strong Bones America. http://www.nbha.org/

20.

https://www.iofbonehealth.org/osteoporosis-european-community-action-plan. Accessed 12 Mar 2018

21.

Hiligsmann M, Bours SP, Boonen A (2015) A review of patient preferences for osteoporosis drug treatment. Curr Rheumatol Rep 17(9):61. https://doi.org/10.1007/s11926-015-0533-0 CrossRefPubMedPubMedCentral

22.

Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S, Treatment of Osteoporosis in clinical Practice Study G (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17(6):914–921. https://doi.org/10.1007/s00198-006-0073-6 CrossRefPubMed

23.

Korownyk C, Kolber MR, McCormack J, Lam V, Overbo K, Cotton C, Finley C, Turgeon RD, Garrison S, Lindblad AJ, Banh HL, Campbell-Scherer D, Vandermeer B, Allan GM (2014) Televised medical talk shows–what they recommend and the evidence to support their recommendations: a prospective observational study. BMJ 349:g7346. https://doi.org/10.1136/bmj.g7346 CrossRefPubMedPubMedCentral

24.

Zeraatkar D, Obeda M, Ginsberg JS, Hirsh J (2017) The development and validation of an instrument to measure the quality of health research reports in the lay media. BMC Public Health 17(1):343. https://doi.org/10.1186/s12889-017-4259-y CrossRefPubMedPubMedCentral

25.

Dumas-Mallet E, Smith A, Boraud T, Gonon F (2017) Poor replication validity of biomedical association studies reported by newspapers. PLoS One 12(2):e0172650. https://doi.org/10.1371/journal.pone.0172650 CrossRefPubMedPubMedCentral

26.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative I (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRef

27.

Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ (2000) A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133(12):933–941CrossRef

28.

Tan O, Harman SM, Naftolin F (2009) What can we learn from design faults in the Women’s Health Initiative randomized clinical trial? Bull NYU Hosp Jt Dis 67(2):226–229PubMed

29.

Gurney EP, Nachtigall MJ, Nachtigall LE, Naftolin F (2014) The Women’s Health Initiative trial and related studies: 10 years later: a clinician’s view. J Steroid Biochem Mol Biol 142:4–11. https://doi.org/10.1016/j.jsbmb.2013.10.009 CrossRefPubMed

30.

McIntosh J, Blalock SJ (2005) Effects of media coverage of Women’s Health Initiative study on attitudes and behavior of women receiving hormone replacement therapy. Am J Health Syst Pharm 62(1):69–74PubMed

31.

Tao M, Teng Y, Shao H, Wu P, Mills EJ (2011) Knowledge, perceptions and information about hormone therapy (HT) among menopausal women: a systematic review and meta-synthesis. PLoS One 6(9):e24661. https://doi.org/10.1371/journal.pone.0024661 CrossRefPubMedPubMedCentral

32.

Buick DL, Crook D, Horne R (2005) Women’s perceptions of hormone replacement therapy: risks and benefits (1980–2002). A literature review. Climacteric 8(1):24–35. https://doi.org/10.1080/13697130500062654 CrossRefPubMed

33.

Whitaker M, Guo J, Kehoe T, Benson G (2012) Bisphosphonates for osteoporosis—where do we go from here? N Engl J Med 366(22):2048–2051. https://doi.org/10.1056/NEJMp1202619 CrossRefPubMed

34.

Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in US patients between 2002 and 2011. J Bone Miner Res 29(9):1929–1937. https://doi.org/10.1002/jbmr.2202 CrossRefPubMedPubMedCentral

35.

Kim SC, Kim DH, Mogun H, Eddings W, Polinski JM, Franklin JM, Solomon DH (2016) Impact of the US Food and Drug Administration’s safety-related announcements on the use of bisphosphonates after hip fracture. J Bone Miner Res 31(8):1536–1540. https://doi.org/10.1002/jbmr.2832 CrossRefPubMedPubMedCentral

36.

Fisher A, Martin J, Srikusalanukul W, Davis M (2010) Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary. Clin Interv Aging 5:355–362. https://doi.org/10.2147/CIA.S13909 CrossRefPubMedPubMedCentral

37.

Sambrook PN, Chen JS, Simpson JM, March LM (2010) Impact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality. Med J Austral 193(3):154–156PubMed

38.

Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. https://doi.org/10.1007/s11657-013-0136-1 CrossRefPubMedPubMedCentral

39.

Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR (2010) Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341:c3691. https://doi.org/10.1136/bmj.c3691 CrossRefPubMedPubMedCentral

40.

Wilkinson E (2010) Calcium pills ‘increase’ risk of heart attack. http://www.bbc.co.uk/news/health-10805062. Accessed 9 Aug 2011

41.

McGreevy C (2010) Influence of recent research findings and associated media coverage on prescribing of calcium and related supplements in the Irish population. BMJ 341:c3691CrossRef

42.

Abola MV, Prasad V (2016) The use of superlatives in cancer research. JAMA Oncol 2(1):139–141. https://doi.org/10.1001/jamaoncol.2015.3931 CrossRefPubMed

43.

Kolata G (2016) Fearing drugs’ rare side effects, millions take their chances with osteoporosis. https://www.nytimes.com/2016/06/02/health/osteoporosis-drugs-bones.html

44.

Khosla S, Cauley JA, Compston J, Kiel DP, Rosen C, Saag KG, Shane E (2016) Addressing the crisis in the treatment of osteoporosis: a path forward. J Bone Miner Res. https://doi.org/10.1002/jbmr.3074 CrossRefPubMedPubMedCentral

45.

Kopecky SL, Bauer DC, Gulati M, Nieves JW, Singer AJ, Toth PP, Underberg JA, Wallace TC, Weaver CM (2016) Lack of evidence linking calcium with or without vitamin D supplementation to cardiovascular disease in generally healthy adults: a clinical guideline from the National Osteoporosis Foundation and the American Society for Preventive Cardiology. Ann Intern Med 165(12):867–868. https://doi.org/10.7326/M16-1743 CrossRefPubMed

46.

Cipriani C, Castro C, Curione M, Piemonte S, Biamonte F, Savoriti C, Pepe J, De Lucia F, Clementelli C, Nieddu L, Minisola S (2015) Acute effect of zoledronic acid on the risk of cardiac dysrhythmias. Intern Emerg Med 10(2):151–156. https://doi.org/10.1007/s11739-014-1125-0 CrossRefPubMed

47.

Corbett JMMM (1999) Medicine, media, and celebrities: news coverage of breast cancer, 1960–1995. J Commun Q 76(2):229–249

Title: Adverse effects of media reports on the treatment of osteoporosis
Authors: Cristiana Cipriani
Jessica Pepe
Salvatore Minisola
E. Michael Lewiecki
Publication date: 01-12-2018
Publisher: Springer International Publishing
Published in: Journal of Endocrinological Investigation / Issue 12/2018
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-018-0898-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2018

Effect of cabergoline monotherapy in Cushing’s disease: an individual participant data meta-analysis

Treating varicocele in 2018: current knowledge and treatment options

Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study

Exophthalmos or pseudo-exophthalmos in the Last Judgement (1535–1541) by Michelangelo Buonarroti (1475–1564)

mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study

The role of ADAMTS4 and ADAMTS9 in cardiovascular disease in premature ovarian insufficiency and idiopathic hypogonadotropic hypogonadism

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials